"Speaking hypothetically about any product whose MOA is to respond to signals of peak inflammation, let's say that product was trialled in adults and didn't demonstrate efficacy, would you then conclude it was unlikely to be effective in children either"
If another randomised, controlled clinical trial failed to show efficacy in adults, i.e. it made no statistical difference whether or not Remestemcel was included in their treatment, then that would be the third clinical trial which showed no efficacy. I woud say it has no apparent efficacy, and put paid to the claims of increased potency. If you still think it might in children then only a randomised, controlled and blinded clinical trial would convince me of that.
"Speaking hypothetically about any product whose MOA is to...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |